Effect of PNPLA3, TM6SF2 and MBOAT7 Genetic Variants on Non-alcoholic Fatty Liver Disease Therapeutic Outcome.

计划入组 92 人 · 首次发布于 2020 年 11 月 23 日

Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (AdipoDROMExpo)

计划入组 600 人 · 首次发布于 2026 年 1 月 9 日

Human Liver ORganoids as a Model to Study the Development of Non-Alcoholic SteatOhepatitis (NASH)

计划入组 60 人 · 首次发布于 2025 年 3 月 4 日

liver disease program

undisclosed drug (fibrotic liver disease/NASH), Engitix/Takeda

PNPLA3

LIVER INSTITUTE PLLC

United States

National Liver Institute

Egypt

National Liver Institute, Egypt

Wave Life Sciences Reports Dose-Dependent Activin E Reductions Up to 85% with WVE-007 in Obesity Trial

Wave Life Sciences Begins Phase 2a Trial of INHBE siRNA WVE-007 Combined With Tirzepatide in Obesity

Evolving Landscape of MASLD: New Insights and Therapeutic Approaches